Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 68788-7897

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-7897). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Delayed Release Cap. Usp 20mg

Label for Duloxetine Delayed-Release Capsules USP 20 mg, generic for Cymbalta, by Preferred Pharmaceuticals Inc. It states each capsule contains 22.4 mg Duloxetine Hydrochloride equivalent to 20 mg Duloxetine. The label includes storage instructions, manufacturer location, and warnings. Directions for use are indicated in both English and Spanish, with space to fill in dosage details and patient information.*

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of Duloxetine Hydrochloride, showing its molecular arrangement including a thiophene ring, phenyl group, and hydrochloride salt formulation.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph showing the proportion of patients with relapse over time in days from randomization, comparing placebo and duloxetine delayed-release capsules treatments. The vertical axis represents the proportion of patients with relapse, and the horizontal axis shows time in days up to 250.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier survival curve graph showing the proportion of patients with relapse over time (in days) from randomization for placebo versus Duloxetine delayed-release capsules. The placebo group is represented by a dashed line indicating a higher relapse proportion versus the solid line for Duloxetine delayed-release capsules.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine (DUL) 60mg BID, Duloxetine 60mg QD, Duloxetine 20mg QD, and placebo, showing a trend of higher patient improvement percentages correlating with increased pain improvement.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60mg BID, Duloxetine 60mg QD, and placebo, showing patient improvement trends across different pain improvement thresholds.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line chart illustrating the percentage of patients improved versus the percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, showing trends in pain improvement across a range of percentages.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph depicting the percentage of patients improved versus the percent improvement in pain from baseline. It compares different dosages of Duloxetine (20 mg, 60 mg, and 120 mg once daily) against a placebo group, showing trends in patient pain improvement across varying thresholds.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows two lines: one for placebo and one for Duloxetine (DUL) 60/120 mg once daily, depicting patient response rates across different pain improvement thresholds.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline (Bocf). Two lines compare placebo (marked with x's) and Duloxetine 60 mg once daily (marked with diamonds), illustrating higher patient improvement percentages with Duloxetine across increasing percent improvements in pain.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It includes two data series: placebo and DULOXETINE 60/120 mg once daily, showing patient response across different pain improvement percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.